Table 2. Study characteristics associated with costs being mentioned in Randomized Controlled Trials.

		Total number	Number of Studies with Actual Costs (%)	Statistical Testing	Number of Studies Mentioning Costs (%)	Statistical Testing
Funding	Industry	68	1 (1%)	p = 0.005*	12 (18%)	p = 0.02*
	Mixed	67	5 (7%)		21 (31%)
	Non-profit	53	8 (15%)		19 (36%)
Conclusion	Negative	37	5 (14%)	p = 0.16*	13 (35%)	p = 0.49*
	Negative But	14	1 (7%)		3 (21%)
	Positive But	34	2 (6%)		8 (24%)
	Positive	103	6 (6%)		28 (27%)
Primary Author's Country	United States	86	4 (5%)	p = 0.12†	25 (29%)	p = 0.52†
	Europe	72	5 (7%)		17 (24%)
	Other	30	5 (17%)		10 (33%)
Study Location	Multi-centered	53	3 (6%)	p = 0.59†	11 (21%)	p = 0.61†
	United States	57	3 (5%)		16 (28%)
	Europe	39	3 (8%)		12 (31%)
	Developing Countries	21	3 (14%)		8 (38%)
	Other	18	2 (11%)		5 (28%)
Product Age	Novel	109	4 (4%)	p = 0.02‡	28 (26%)	p = 0.51‡
	Established	79	10 (13%)		24 (30%)

*Cochran-Armitage test.

^†Fisher-Freeman-Halton test.

^‡Fisher's exact test.